Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies. Find out more about cookies.

Click here to dismiss this banner

YOU MIGHT BE INTERESTED IN

  1. Stem Cell Technologies: World Market Outlook 2013-2023

    Stem Cell Technologies: World Market Outlook 2013-2023

    What are the commercial prospects for stem cells? Visiongain's updated report predicts revenues to 2023. There you find the best places for sales growth, also understanding trends, technologies, therapies, and opportunities. That study gives you revenue forecasts to 2023 for the overall world market and its submarkets. See what's happening for those cellular technologies, finding how you can gain.

    ...more details
  2. Translational Regenerative Medicine: Market Prospects 2011-2021

    Translational Regenerative Medicine: Market Prospects 2011-2021

    What are the commercial prospects for regenerative medicine? Our new report shows you potential revenues to 2021, discussing opportunities and market prospects. Our study identifies three main areas: tissue engineering, stem cell therapy and gene therapy.

    ...more details
  3. Neuroprotective Products: World Market Prospects 2012-2022

    Neuroprotective Products: World Market Prospects 2012-2022

    What are the commercial prospects for neuroprotective treatments? Visiongain's new report shows you potential revenues and trends to 2022, discussing data, opportunities and outlooks. Many neuroprotective products are in development. Our study lets you assess projected sales at overall world market, therapeutic submarket and product level to 2022. In particular, how will 11 products - including Rasagiline, Minocycline, Memantine and NeuroSTAT - perform to 2022?

    ...more details
  4. Hepatitis Treatments and Vaccines: World Market 2012-2022

    Hepatitis Treatments and Vaccines: World Market 2012-2022

    Where is the hepatitis treatment market heading? Visiongain's new report shows you potential revenues and trends to 2022, discussing data, opportunities and prospects. This study investigates drugs and vaccines for treating hepatitis - existing and pipeline products. You assess projected sales at world market, therapeutic submarket, product and national level to 2022.

    ...more details
  5. Ophthalmic Drugs: World Market Prospects 2012-2022

    Ophthalmic Drugs: World Market Prospects 2012-2022

    What are the commercial prospects for treating eye disorders? Visiongain's report shows you potential revenues to 2022 - data, forecasts and discussions. How will 20 leading ophthalmic drugs - including Lucentis, Visudyne, Xalatan/Xalacom and Restasis - perform from 2012? Our investigation gives you business research and analysis with sales forecasts. Find coverage of the R&D pipeline too, by therapeutic area, assessing trends and outlooks.

    ...more details
  6. Macular Degeneration (AMD) and Diabetic Retinopathy (DR): World Drug Market 2011-2021

    Macular Degeneration (AMD) and Diabetic Retinopathy (DR): World Drug Market 2011-2021

    What are the commercial prospects for the treatment of macular degeneration (AMD) and diabetic retinopathy (DR)? Our new report shows you potential revenues to 2021, discussing commercial opportunities and prospects. Discover potential revenues at total world, submarket, product and national levels.

    ...more details
  7. Epigenetic Therapies and Technologies: World Market Prospects 2013-2023

    Epigenetic Therapies and Technologies: World Market Prospects 2013-2023

    What does the future hold for epigenetic applications? Visiongain's new report gives you revenue predictions to 2023 for those therapies, technologies and diagnostic products. There you find sales data, R&D trends, opportunities and commercial prospects. That analysis lets you assess forecasted sales at overall world market, submarket, product, regional and national level. You discover the potential of the industry and market for epigenetics, seeing where that field is heading.

    ...more details
  8. Cell-Based Assays: World Market Prospects 2013-2023

    Cell-Based Assays: World Market Prospects 2013-2023

    Find what the future holds for cell assay technologies. Visiongain's updated report gives you revenue predictions to 2023. There you discover sales data, R&D trends, opportunities and prospects. You find the potential of those biotechnologies. See forecasted sales at overall world market, submarket and national level. Also you assess emerging trends and predicted events. Many opportunities remain - you discover the areas to prosper.

    ...more details

PHARMA REPORT

rss_Pharma.jpg...see all
Stem Cell Technologies: World Market Outlook 2012-2022

Stem Cell Technologies: World Market Outlook 2012-2022

  • Publication date: 23/05/2012
  • Number of Pages: 202
  1. Report Details
  2. Table of Contents
  3. Companies Listed

Report Details

Why the stem cells market will expand - discover its commercial potential

What does the future hold for stem cells in medicine? Visiongain's report shows you potential revenues to 2022, assessing data, trends, opportunities and prospects there.

That new study lets you assess projected sales at world market and submarket level. You see discussions of work on stem cells in leading countries too - outlooks, challenges, patenting and regulations.

You see forecasting of world-level submarkets to 2022, finding potential revenues:
• Stem cell therapies
• Stem cell banks (e.g., cord blood banking)
• Ancillaries - adjunct technologies.

The technology is changing medicine through new therapies, methods and applications in drug development. Its scope is vast and promising, despite challenges.

With our study you also assess the R&D pipeline, seeing trends and outlooks. You find discussions of treatments in development, by therapeutic area and organisation:
• Autoimmune diseases - modifying the immune system
• Diabetes - restoring pancreatic function
• Oncology and cancer treatment
• Cardiovascular diseases - healing the heart and vascular system
• Neurological and cerebrovascular disorders - regenerating CNS tissue
• Ophthalmic disorders - potential for overcoming sight loss
• Bioartificial livers and hepatic regeneration with stem and progenitor cells
• Dermatology - developments in cellular skin repair
• Adipose-derived stem cells for autologous treatments
• Regenerative dentistry - potential for biotechnological tooth replacement.

You find prospects for embryonic, adult and induced pluripotent stem cells from 2012.

Market value for 2014 and prospects for the future

What will happen next? The biotechnology industry will develop many products using stem cells and increase revenues there from 2012 to 2022. The R&D pipeline is extensive. Overall world revenue will reach $7.3bn in 2014, our report forecasts.

Expansion of the market will result from new stem cell treatments and increased uptake of those technologies in drug development assays.

A diverse pipeline of therapies offers hope for treating many diseases. There are potential cures for diabetes, HIV and dry age-related macular degeneration (AMD).

Stem cell-based innovations tackle cardiovascular disorders, autoimmune diseases, metabolic disorders and many other conditions. Some of the breakthroughs will be a commercial reality by 2022, our investigation predicts.

What are companies doing? Our work profiles 187 organisations and investigates prospects of the industry and market. Examples include these developers and producers:
• Advanced Cell Technology
• Athersys
• Baxter Healthcare
• Bioheart
• Cytori Therapeutics
• Gamida Cell
• Mesoblast
• NeoStem
• Osiris Therapeutics
• TiGenix.

The scope of the field is widening, with many organisations entering and collaborating. You see how.

Haematopoietic stem cell transplantation is an established treatment. Revenues from transplants of bone marrow, peripheral blood and umbilical cord blood form much of the market in 2012. Those activities form a beginning, with many advances possible by 2020.

There are many commercial opportunities in stem cells, with high revenues possible from 2012 to 2022. New products will change medicine. Our report shows you and explains.

Forecasts, market shares, developmental trends, commercial news and discussions

In visiongain's report you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP), company profiles and discussions of R&D activities. You receive 40 tables, 20 charts and six research interviews.

Eight ways Stem Cell Technologies: World Market Outlook 2012-2022 helps you

In particular, our study gives you the following knowledge on the topic:
• Find potential revenues to 2022 for the overall world market and submarkets
• Assess 187 prominent organisations, discovering activities and outlooks
• See discussions of stem cell work in the US, the UK, other prominent European countries, Israel, Japan, India, China and South Korea
• Review R&D pipelines, seeing trends and progress by therapeutic area
• Investigate competition and opportunities influencing sales
• Find out what will stimulate and restrain the industry and market
• Analyse prospects for established companies and those seeking to enter the sector
• View opinions from our survey, seeing interviews with authorities.

There, you discover quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed on business intelligence.

Without our report you could miss out on information that your competitors use.

Gain research and analysis now for stem cells in healthcare

Our study is for everybody needing industry and market analyses for stem cells in medicine. You find data, predictions and answers there. Please order that report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6 

Table of Contents

1. Executive Summary
1.1 Overview of Findings
1.2 Chapters in the Report
1.3 Research and Analysis Methods

2. Stem Cells: An Introduction
2.1 What Are Stem Cells?
2.2 Potency and Differentiation
2.3 Embryonic Stem Cells
2.4 Adult Stem Cells
2.4.1 Haematopoietic Stem Cells
2.4.2 Mesenchymal Stem Cells
2.4.3 Adipose-Derived and Other Stromal Stem Cells
2.4.4 Neural Stem Cells
2.4.5 Other ASCs
2.5 Induced Pluripotent Stem Cells
2.6 Autologous and Allogeneic Properties
2.7 Stem Cells in Medicine: Past, Present and Future

3. The World Stem Cells Market 2012-2022: Overview
3.1 The Stem Cells Market, 2012
3.2 Stem Cells Market Forecast 2012-2022
3.3 Stem Cells Market Segmentation
3.4 What is a Stem Cell Therapy?
3.5 Stem Cells, Progenitor Cells, Cellular Therapies, and Regenerative Medicine
3.6 What is a Stem Cell Product? A Note on the Stem Cell Transplant Market

4. Stem Cell Therapies Market, 2012-2022
4.1 World Market Forecast, 2012-2022
4.2 Existing Stem Cell Therapies, 2012
4.3 Haematopoietic Stem Cell Transplantation Market, 2012
4.3.1 Therapeutic Effectiveness of Stem Cell Transplantation
4.3.2 Graft Versus Host Disease and Other Factors in Stem Cell Transplantation
4.4 World Stem Cell Treatments Market, 2012
4.5 Stem Cell Orthobiologics, 2012
4.5.1 The Use of Stem Cells in Orthobiologics
4.5.2 NuVasive - the Osteocel Product Family
4.5.3 Orthofix - The Trinity Bone Matrix
4.5.4 Osteotech - Harvesting Autologous Bone Marrow Stem Cells
4.5.5 Skye Orthobiologics - Soft Tissue Repair with a Cellular Matrix
4.5.6 SpineSmith - Point-of-Care Bone Marrow Cells for the Spine
4.5.7 RTI Biologics - Rolling Out Stem Cell Orthobiologics from 2012?
4.5.8 BioMet Orthopedics - Trialling the MarrowStim Concentration Kit
4.5.9 MedCell Bioscience - Tendon Therapies
4.5.10 Banc de Sang i Teixits - Bone Repair in Catalonia
4.5.11 Apatech - Observing Outcomes for Stem Cell Grafts
4.5.12 Other Companies in Stem Cell Orthobiologics
4.6 Other Approved Stem Cell Products, 2012
4.6.1 FCB-Pharmicell - Hearticellgram-AMI, the First Approved Product of its Kind
4.6.2 Anterogen - Cupistem, Adipose-Derived Stem Cells for Anal Fistula
4.6.3 Medipost - Cartistem
4.7 Late-Stage Pipeline for Stem Cell Therapeutics
4.7.1 Aastrom Biosciences - Ixmyelocel-T for Critical Limb Ischemia
4.7.2 Gamida Cell - StemEx: A Cord Blood Blockbuster?
4.7.3 Mesoblast - 40-Fold Expansion of Cord Blood Stem Cells
4.7.4 Osiris Therapeutics - Prochymal
4.7.5 Baxter Healthcare - Autologous CD34 Positive Cells for Heart Disease
4.7.6 TiGenix - Cx601 for Complex Perianal Fistula
4.7.7 Bioheart - MyoCell in MARVEL Trial
4.7.8 Cytori Therapeutics - Adipose-Derived Cells for Acute Myocardial Infarction
4.7.9 Stempeutics Research - First Stem Cell Approval in the Indian Market?
4.8 Pipeline for Stem Cell Transplantation Ancillary Products
4.8.1 Mobilisation/Engraftment / Graft Enhancement
4.8.1.1 Bayer - GM-CSF for Mobilisation and other Trials
4.8.1.2 Biokine Therapeutics - BKT140 for Stem Cell Mobilisation and Myeloma Cell Destruction
4.8.1.3 Biothera - Imprime PGG for Progenitor Mobilisation
4.8.1.4 Celldex Therapeutics - CDX-301 Protein to Enhance Harvesting
4.8.1.5 Cytheris - Interleukin-7 for Immune Reconstitution
4.8.1.6 Eisai - Treatments for Sepsis, Nausea and Immune Enhancement
4.8.1.7 Fate Therapeutics - ProHema for Pharmacological Enhancement
4.8.1.8 Genzyme - Plerixafor in Label-Extension Trials
4.8.1.9 Noxxon Pharma - Spiegelmers for Mobilisation
4.8.1.10 Shenzhen Zhongxing Yangfan Biotech - Ex Vivo Activated Immune Cells
4.8.1.11 Systemix - RevM10 Gene Therapy Trial
4.8.1.12 Polyphor - Small Molecule Mobilisation Enhancement
4.8.1.13 TaiGen Biotechnology - Burixafor for Stem Cell Mobilisation
4.8.1.14 Tarix Pharmaceuticals - TXA127 Peptide for Peripheral Stem Cell Populations
4.8.1.15 Xcyte Therapies - Xcellerate Technology for Improving Implantation Outcomes
4.8.2 Anti-Graft versus Host Disease
4.8.2.1 Alder Biopharmaceuticals - ALD518 Antibody
4.8.2.2 AstraZeneca - MEDI-507 for Paediatric Patients
4.8.2.3 Fresenius Biotech - Polyclonal Antibody for Prophylaxis
4.8.2.4 Kiadis Pharma - ATIR for Allogeneic Transplant Enhancement
4.8.2.5 MolMed - Genetically Engineering Lymphocytes
4.8.2.6 PDL BioPharma - Visilizumab in Trials
4.8.2.7 Rafa Laboratories - Budesonide as New Steroid Option
4.8.2.8 Regimmune - Immunomodulator for Allogeneic Transplants
4.8.2.9 Therakos - Photophoresis of Peripheral Blood Cells
4.8.3 New Anti-Infectives
4.8.3.1 AM-Pharma - Antifungal Peptide Trials
4.8.3.2 Astellas Pharma - Micafungin for Paediatric Transplant Recipients
4.8.3.3 Cell Medica - Antiviral Cell Therapies
4.8.3.4 Chimerix - CMX001 Targets Cytomegalovirus
4.8.3.5 Enzon Pharmaceuticals - Anti-Infective Recombinant Lectin Concept
4.8.3.6 Gilead Sciences - AmBisome as Allogeneic Adjunct
4.8.3.7 Johnson & Johnson - Janssen Trialling Antifungal Prophylaxis
4.8.3.8 Merck & Co. - Antifungals for Allogeneic Transplant Assistance
4.8.3.9 Vical - Cytomegalovirus Vaccine Candidate
4.8.3.10 ViroPharma - Maribavir Antiviral in Phase III
4.8.3.11 Xiamen Amoytop Biotech - Biological Anti-Infectives from Shanghai
4.8.4 New Treatments for Combination
4.8.4.1 Abbott - Leuprolide Acetate Depot in Haematological Malignancies
4.8.4.2 AiCuris - AMD3100 in Trials with Busulfan and Other Combinations
4.8.4.3 Alizyme - ATL-104 Targets Mucous Membrane Inflammation
4.8.4.4 Biogen Idec - Combining Radio-Immunotherapy with Transplantation
4.8.4.5 Celator Pharmaceuticals - Acute Myelogenous Leukaemia Candidate
4.8.4.6 CyDex Pharmaceuticals - New Chemotherapeutics in Development
4.8.4.7 Incyte - JAK Inhibitor for Haematological Malignancies
4.8.4.8 Medac - Specialising in the Malignancies Segment
4.8.4.9 Molecular Insight Pharmaceuticals - Iodine-131 Radio-Immunoconjugate Trial
4.8.4.10 Otsuka Pharmaceutical Development & Commercialization - Further Busulfan Trials
4.8.4.11 Pierre Fabre Medicament - Radiotherapy and Chemotherapy Combinations
4.8.4.12 Poniard Pharmaceuticals - Radiation Treatments
4.8.4.13 Swedish Orphan Biovitrum - Oral Mucositis Candidate
4.8.4.14 Spectrum Pharmaceuticals - More Zevalin Combinations
4.8.4.15 TAP Pharmaceutical Products - Secondary Amenorrhea in Transplant Patients
4.8.4.16 Vion Pharmaceuticals - New Alkylating Agent

5. Medium and Long-Term Stem Cell Therapies Pipeline, 2012
5.1 Overview of the Stem Cell Pipeline, 2012
5.2 Oncology: Cancer Stem Cells and Other New Treatment Possibilities
5.2.1 Amgen: Cell Transplantation for Metastatic Renal Cell Carcinoma
5.2.2 Cellerant Therapeutics - Engraftment Enhancement and a Cancer Stem Cell Antibody
5.2.3 ImmunoCellular Therapeutics - Glioblastoma Stem Cell Target
5.2.4 Immunovative Therapies - Mirroring the Stem Cell Transplantation Anticancer Effect
5.2.5 Novartis Pharmaceuticals - Cord Blood Transplant Candidate
5.2.6 Ribozyome - Stem Cell Gene Therapy Concept for Hodgkin's Lymphoma
5.3 Autoimmune Diseases - Using Stem Cells to Reset the Immune System
5.3.1 Alliancells Bioscience Corporation - Possible Rheumatoid Arthritis Treatment
5.3.2 AlloCure - AC607 for Anti-Inflammatory Effects
5.3.3 Athersys - MultiStem for Autoimmune and Other Disorders
5.3.4 Celgene Corporation - Placental Tissue Stem Cells for Rheumatoid Arthritis and Others
5.3.5 HomeoTherapy - Mesenchymal Stem Cells for GvHD
5.3.6 ViroMed - Stem Cell Gene Therapy for Chronic Granulomatous Disease
5.4 Diabetes - Stem Cells to Restore Pancreatic Function
5.4.1 Cellonis Biotechnology - Commercializing Peking University Research on Stem Cells in Diabetes
5.4.2 Ixion Biotechnology - Liver Stem Cells for Insulin Production
5.4.3 MaRS Innovation - Diabetes Partnership with Mount Sinai Hospital
5.4.4 ViaCyte - Encaptra System for ESC-Produced Pancreatic Precursors
5.5 Cardiological/Cardiovascular Diseases - Stem Cells to Heal the Heart and Vascular System
5.5.1 Aldagen - Proprietary Cells for Ischemic Conditions
5.5.2 Apceth - Mesenchymal Stem Cells for Advanced Peripheral Arterial Occlusive Disease
5.5.3 Athersys - Angiotech Collaboration
5.5.4 Biogenea-Cellgenea - Cardiogenea for Myocardial Infarction
5.5.5 Capricor - Using Cardiosphere-Derived Cells for Heart Repair
5.5.6 Cardio3 Bioscience - Cardiopoiesis Platform for Heart Regeneration
5.5.7 Cardiogenesis Corporation - Lasers and Stem Cells for Revascularisation
5.5.8 Eli Lilly and Company: Collaborating on Intracoronary Injection of Progenitor Cells Trial
5.5.9 Garnet BioTherapeutics - GBT009 for Cardiac Tissue Preservation
5.5.10 Medistem - Endometrial Regenerative Cells for Critical Limb Ischemia
5.5.11 Neostem - AMR-001 for Myocardial Infarction
5.5.12 Northern Therapeutics - Gene Therapy for Pulmonary Arterial Hypertension
5.5.13 OrbusNeich - Coronary Stent Activates Endogenous Cell Populations
5.5.14 Pluristem Therapeutics - Placental Stem Cells for Peripheral Artery Disease
5.5.15 Regenetech - Heart Disease Treated with NASA-Derived Tissue Technology
5.5.16 TCA Cellular Therapy - Mesendo Autologous Treatments
5.6 Neurological/Cerebrovascular Disease - Regenerating Brain, Nerves and Vasculature
5.6.1 New Paradigms in Neurodegenerative Disease Treatment
5.6.2 BrainStorm Cell Therapeutics - NurOwn Cells for Spinal Cord Injury and ALS
5.6.3 Corestem - Autologous Bone Marrow Stem Cells for ALS
5.6.4 Geron Corporation - ESC Pioneer
5.6.5 Neuralstem - Neural Stem Cells for Synaptic Repair and Neuroprotection
5.6.6 NeuroGeneration - Parkinson's Treatment with Autologous Neural Stem Cells
5.6.7 NsGene - Encapsulated Cell Biodelivery System
5.6.8 Proneuron Biotechnologies - CNS Cellular Therapies
5.6.9 ReNeuron - Foetally-Derived CTX Cells for Stroke
5.6.10 Renovo Neural - Cellular Multiple Sclerosis Treatments
5.6.11 RhinoCyte - Stem Cells from the Nasal Passage to the Spinal Cord
5.6.12 Saneron CCEL Therapeutics - U-CORD-CELL Preclinical Platform
5.6.13 StemCells - Clinical Trials in Batten Disease and Others
5.6.14 Stem Cell Therapeutics - NTx-265 for Stroke
5.6.15 SanBio - SB623 for Ischemic Stroke
5.6.16 Stemedica Cell Technologies - Ischemic Tolerant Stem Cell Platform
5.6.17 Theradigm - Neural Cells for CNS Disorders
5.6.18 Titan Pharmaceuticals - Dopaminergic Cell Treatment Concept
5.7 Ophthalmic Disease - Chief Focus for ESC Clinical Work
5.7.1 ArBlast - Treating Corneal Disorders and Other Diseases
5.7.2 Advanced Cell Technology - Leading the Field in ESC Clinical Trials
5.7.3 Biotime - Targeting AMD with ESCs
5.7.4 CellSeed - CAOMECS for Cornea Repair
5.7.5 Pfizer - Collaborating on the London Project to Cure Blindness
5.8 Other Areas of Investigation for Stem Cell Therapies
5.8.1 Alliqua - HepaMate Bioartificial Liver and Stem Cells
5.8.2 CellTran - Cellular Skin Repair Products
5.8.3 GlaxoSmithKline - Collaborating with Harvard Stem Cell Institute
5.8.4 Histogen - Hair Stimulating Complex Contains Stem Cell Factor
5.8.5 IntelliCell Biosciences - Adipose-Derived Stem Cells for Autologous Treatments
5.8.6 Intercytex - Formerly Owned Axordia Stem Cell Research
5.8.7 iPierian - IPSC Expertise
5.8.8 Medtronic - Links to MG Biotherapeutics and Tengion
5.8.9 Odontis - BioTooth for Dental Replacement Concept
5.8.10 Roche - Research Collaborations in the Field
5.8.11 S-Evans Biosciences - Menstrual Stem Cells for Hepatic Disease
5.8.12 Tengion - Neo-Organs from Progenitor Cells
5.8.13 Tissue Genesis - First Point-of-Care Study of Adipose-Derived Stem Cells to be FDA-Approved
5.8.14 Vesta Therapeutics - Regenerating the Liver with Stem and Progenitor Cells

6. Stem Cell Banking Market, 2012-2022
6.1 World Market Forecast, 2012-2022
6.2 Health Insurance for the Cellular Therapy Century: Overview of the Stem Cell Banking Field
6.3 Selected Companies in the Stem Cell Banking Field
6.3.1 Amstem Corporation - Former Leader in the Field
6.3.2 China Cord Blood Corporation - China's Biggest Blood Bank
6.3.3 Cord Blood America - Presence in the US, Latin America and Europe
6.3.4 Cryo-Cell - First Private Cord Blood Bank
6.3.5 CryoCord - Leaders in Malaysia
6.3.6 Cryo-Save - Europe's Largest Stem Cell Bank
6.3.7 General BioTechnology - Stem Cells for Banking and Veterinary Therapies
6.3.8 InSCeption Biosciences - Canada's Biggest Cord Blood Programme
6.3.9 International Stemcell Services - First Indian Umbilical Cord Blood Bank
6.3.10 LifebankUSA - First Transplanted Placental Cells
6.3.11 Lifebank Cryogenics - Canada's First Cord Blood Bank
6.3.12 Stem Cell Authority - Banking Mesenchymal Cells
6.3.13 Stem Cell Sciences - Banking Adult Haematopoietic Stem Cells
6.3.14 StemCyte - High Stem Cell Yield
6.3.15 ViaCell - ViaCord Umbilical Cord Blood Bank

7. Stem Cell Ancillaries Market, 2012-2022
7.1 World Market Forecast, 2012-2022
7.2 Overview of Stem Cell-Related Business Models, 2012
7.3 Stem Cell Assays: An Important Field
7.3.1 Axiogenesis - In Vitro Disease Models
7.3.2 Cellectis Group - First Marketed Cardiomyocytes and Hepatocytes Derived from ESCs
7.3.3 Cellular Dynamics International - Leader in IPSC Technology
7.3.4 CXR Biosciences - Drug Development and Toxicology Services
7.3.5 Maxcyte - Stem Cells in Early Phase Drug Discovery
7.3.6 Stemina Biomarker Discovery - ESCs and Metabolomics
7.4 Stem Cell Supply and Processing: Products and Services
7.4.1 3DM - PuraMatrix for Cell Culturing
7.4.2 Adistem - Extraction and Activation Technology Platform
7.4.3 AllCells - Stem Cell Line Supplier
7.4.4 Angel Biotechnology - Stem Cell Contract Biomanufacturing
7.4.5 Antria - Regenerative Medicine Contract Research Organisation
7.4.6 Arteriocyte - Nanex Culturing and Expansion Technology
7.4.7 BioE - Marketing the First Multipotent Clonal Stem Cell Line from Umbilical Cord Blood
7.4.8 Bio-Matrix Scientific Group - Stem Cell Cryobanking, Research and Partnerships
7.4.9 Cognate BioServices - Custom Manufacture and Testing of Stem Cells
7.4.10 EpiStem - Epithelial Stem Cell Specialists
7.4.11 FortiCell Bioscience - Biomaterials Technology Platforms
7.4.12 Global Stem - Growth Media, Reagents and Other Stem Cell Tools
7.4.13 Miltenyi Biotec - MACSQuant Analyzer and Other Stem Cell Tools
7.4.14 Plasticell - CombiCult Differentiation Platform
7.4.15 Roslin Cellab - ESC Lines and Other Resources
7.4.16 StemCell Technologies - Stem Cell Culturing, Isolation, Training and Other Services
7.4.17 StemCore - Pluripotent Cell Lines and Outsourcing Services
7.4.18 Stemride International - Normal and Abnormal ESC Lines
7.4.19 Vitro Biopharma - Tools for Stem Cell and Drug Development
7.5 Supporting Technologies
7.5.1 BioLife Solutions: HypoThermosol and CryoStor Biopreservation
7.5.2 CellCentric: Epigenetics and Cell Reprogramming Expertise
7.5.2.1 Stem Cells and Epigenetics: Brief Discussion
7.5.3 CellCyte Genetics - CCG-E45 Culture Chamber
7.5.4 Covance - Heavy Involvement with Biological Drug Development
7.5.5 ThermoFisher Scientific - Instruments, Equipment, Software and Other Medical Technology
7.5.6 ThermoGenesis - BioArchive System and Other Proprietary Technologies

8. Stem Cells Market Regional Overview 2012
8.1 US: Controversy and Venture Capital
8.2 UK: Leading the Way in Europe
8.3 Europe: Mixed Responses
8.4 Israel: A Nexus of Stem Cell Innovation
8.5 Japan: Home of IPSC Research
8.6 India: High Activity in the Field
8.7 China: A Potential Leader in Stem Cells
8.8 South Korea: First to Approve Stem Cell Treatments

9. Main Research Interviews from Our Survey
9.1 Interview with Dr Alan Trounson, President, California Institute for Regenerative Medicine (CIRM)
9.1.1 Current Stem Cell Clinical Trials
9.1.2 Big Pharma Investment in Stem Cells
9.1.3 Mesenchymal Cells in Clinical Trials
9.1.4 Definitions of Cell Types and Regulatory Pathways
9.1.5 The Prospects for Stem Cell Cures
9.2 Interview with Nick Bassil, Partner, Kilburn & Strode LLP
9.2.1 Overview of the Stem Cell Patent Landscape
9.2.2 The Aftermath of the Brüstle Case
9.2.3 Details and Consequences of the Brüstle Ruling
9.2.4 Patenting Adult Stem Cells and Induced Pluripotent Stem Cells
9.2.5 Stem Cell Regulation and Stem Cell Ethics
9.3 Interview with Dr Kieran Breen, Director of Research and Innovation, Parkinson's UK
9.3.1 Damage to Neural Matter Caused by Parkinson's Disease
9.3.2 The Limitations for Stem Cell Treatment of Parkinson's Disease
9.3.3 The Therapeutic Prospects for Induced Pluripotent Stem Cells
9.3.4 The Likelihood of a Sustained Response to Regenerative Treatments of Parkinson's Disease
9.4 Interview with Jason Kolbert, MBA, Vice President of Strategic Business Development, NeoStem
9.4.1 NeoStem's Business Model
9.4.2 NeoStem's AMR-001 Candidate
9.4.3 The Regulatory and Commercial Challenges for AMR-001
9.4.4 NeoStem's VSEL and Blood Banking Platforms
9.4.5 The Broader Stem Cell Therapies Market to 2022
9.5 Interview with Mr Felix von Haniel, Director, Business Development, Axiogenesis
9.5.1 Axiogenesis' Tissue Production Platform
9.5.2 Modelling Cardiac Hypertrophy
9.5.3 Future Trends in the Stem Cells Assays Market
9.5.4 The Potential for iPSCs

10. Conclusions
10.1 Strengths: Stem Cells Have Proven Clinical and Commercial Value
10.2 Weaknesses: The Field is Still in its Infancy
10.3 Opportunities: A Revolution in Medicine?
10.4 Threats: A Controversial Field
10.5 Concluding Remarks

List of Tables
Table 2.1 Potency and Source of Stem Cells
Table 2.2 Germ Layers and Their Associated Types of Cells and Organs
Table 2.3 Sources of Stem Cells for Medical Applications, 2012
Table 3.1 Stem Cells Market by Segment: Revenues ($m), Market Shares (%), 2011
Table 3.2 Stem Cells Market by Segment: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2011-2016
Table 3.3 Stem Cells Market by Segment: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2017-2022
Table 4.1 Stem Cell Therapies Market: Revenues ($m), AGR (%), CAGR (%), Overall Market Shares (%), 2011-2016
Table 4.2 Stem Cell Therapies Market: Revenues ($m), AGR (%), CAGR (%), Overall Market Shares (%), 2017-2022
Table 4.3 Medicare Coverage for HSCT, 2012
Table 4.4 Malignancies and Other Haematological Diseases Treated with HSCT, 2012
Table 4.5 Comparative Characteristics of Bone Marrow, Peripheral Blood and Cord Blood for HSCT, 2012
Table 4.6 Orthobiologics Market: Segment Revenues ($bn) and Market Shares (%), 2011
Table 4.7 Selected Players in Stem Cell Orthobiologics
Table 4.8 Companies with Stem Cell Products Approved by the Korean FDA
Table 4.9 Selected Approved (Non-Stem Cell) Cellular Therapies, 2012
Table 4.10 Stem Cell Therapies in Phase III Development, 2012
Table 4.11 Selected Non-Industry Sponsored Phase III Stem Cell Trials, 2012
Table 4.12 Aastrom Biosciences' Currently-Listed Clinical Trials Involving Stem Cells, 2012
Table 4.13 Gamida Cell's Currently-Listed Clinical Trials Involving Stem Cells, 2012
Table 4.14 Mesoblast's Currently-Listed Clinical Trials Involving Stem Cells, 2012
Table 4.15 Osiris Therapeutics' Currently-Listed Clinical Trials Involving Stem Cells, 2012
Table 4.16 Baxter Healthcare's Currently-Listed Clinical Trials Involving Stem Cells, 2012
Table 4.17 Cellerix's Currently-Listed Clinical Trials Involving Stem Cells, 2012
Table 4.18 Bioheart's Currently-Listed Clinical Trials Involving Stem Cells, 2012
Table 4.19 Cytori Therapeutics' Currently-Listed Clinical Trials Involving Stem Cells, 2012
Table 4.20 Stempeutics Research's Currently-Listed Clinical Trials Involving Stem Cells, 2012
Table 4.21 Selected Companies with Candidate Stem Cell Transplantation Ancillary Products, 2012
Table 5.1 Quantity of Stem Cell Clinical Trials by Indication, 2012
Table 5.2 Selected Companies Developing Stem Cell Treatments for Cancer, 2012
Table 5.3 Selected Companies Developing Stem Cell Autoimmune Treatments, 2012
Table 5.4 Selected Companies Developing Stem Cell Diabetes Treatments, 2012
Table 5.5 Selected Companies Developing Stem Cell Cardiological/Cardiovascular Treatments, 2012
Table 5.6 Selected Companies Developing Stem Cell Neurological/Cerebrovascular Treatments, 2012
Table 5.7 Selected Companies Developing Stem Cell Ocular Treatments, 2012
Table 6.1 Stem Cell Banking Market: Revenues ($m), AGR (%), CAGR (%), Overall Market Shares (%), 2011-2016
Table 6.2 Stem Cell Banking Market: Revenues ($m), AGR (%), CAGR (%), Overall Market Shares (%), 2017-2022
Table 6.3 Reported Fees of Various Private Stem Cell Blood Banks Worldwide, 2011
Table 7.1 Stem Cell Ancillaries Market: Revenues ($m), AGR (%), CAGR (%), Overall Market Shares (%), 2011-2016
Table 7.2 Stem Cell Ancillaries Market: Revenues ($m), AGR (%), CAGR (%), Overall Market Shares (%), 2017-2022
Table 7.3 Selected Companies Offering Stem Cell-Based Assays, 2012

List of Figures
Figure 2.1 The Early History of Stem Cell Discovery and Development
Figure 3.1 Stem Cells Market by Segment: Revenues ($m), Market Shares (%), 2011
Figure 3.2 Stem Cells Market by Segment: Revenues ($m), 2011-2016
Figure 3.3 Stem Cells Market by Segment: Revenues ($m), 2017-2022
Figure 4.1 Stem Cell Therapies Market: Revenues ($m), 2011-2016
Figure 4.2 Stem Cell Therapies Market: Revenues ($m), 2017-2022
Figure 4.3 Orthobiologics Market Shares (%), 2011
Figure 5.1 Quantity of Stem Cell Clinical Trials (All Phases) by Indication, 2012
Figure 5.2 Oncology Stem Cell Clinical Trials by Phase, 2012
Figure 5.3 Cardiological/Cardiovascular Stem Cell Clinical Trials by Phase, 2012
Figure 5.4 Autoimmune, Diabetes, Neurological and Ophthalmological Stem Cell Clinical Trials by Phase, 2012
Figure 5.5 Pfizer's Stem Cell Collaborations, 2008-2012
Figure 6.1 Stem Cell Banking Market: Revenues ($m), 2011-2016
Figure 6.2 Stem Cell Banking Market: Revenues ($m), 2017-2022
Figure 6.3 Reported Twenty-Year Storage Costs at Various Private Cord Blood Banks Worldwide, 2011
Figure 7.1 Stem Cell Ancillaries Market: Revenues ($m), 2011-2016
Figure 7.2 Stem Cell Ancillaries Market: Revenues ($m), 2017-2022
Figure 7.3 High Profile Toxicity-Related Pharmaceutical Product Withdrawals, 1991-2010
Figure 7.4 Pharmaceutical R&D Spending by Developmental Stage, 2010
Figure 10.1 Stem Cell Market Segments: Revenues ($m), 2011-2022 

Companies Listed

12th Guangzhou Municipal Hospital
3DM
Aastrom Biosciences
Abbott
Adistem
Advanced Cell Technology
Ageless Regenerative Institute
AiCuris
Aldagen
Alder Biopharmaceuticals
Alizyme
AllCells
Alliancells Bioscience Corporation
Alliqua
AlloCure
American Association of Blood Banks
Amgen
Amorcyte
AM-Pharma
Amstem Corporation
Angel Biotechnology
Angioblast
Angiotech
Anterogen
Antria
Apatech
Apceth
Applied Tissue Technologies
ArBlast
Arrow Therapeutics
Astellas Pharma
AstraZeneca
Aurigen Ventures
Aristotle University of Thessaloniki
Axcan Pharma
Arteriocyte
Athersys
Axiogenesis
Banc de Sang i Teixits
Barts & The London NHS Trust
Baxter Healthcare
Bayer
Beike Biotechnology
Beth Israel Deaconess Medical Center
BioE
Biogenea-Cellgenea
Biogen Idec
Bioheart
Biokine Therapeutics
BioLife Solutions
Biologic Therapies
Bio-Matrix Scientific Group
BioMet Orthopedics
BioMimetic Therapeutics
Biothera
Biotime
BrainStorm Cell Therapeutics
Bresagen
Cairo University
California Institute for Regenerative Medicine (CIRM)
Canadian Blood Services
Capricor
Capsant Neurotechnologies
Cardio3 Bioscience
Cardiogenesis Corporation
Celator Pharmaceuticals
Celgene Corporation
Cellartis
CellCentric
CellCyte Genetics
Celldex Therapeutics
Cell Dynamics
Cellectis
Cellerant Therapeutics
Cellerix
Cell Genesys
Cellgenia
CellGenix
Cell Medica
Cellonis Biotechnology
CellSeed
Cell Therapeutics
CellTran
Cellular Dynamics International
Center for International Blood and Marrow Transplant Research
Cephalon
Ceregene
Cha General Hospital, Seoul
Chimerix
Children's Hospital Los Angeles
Children's Memorial Hospital
Children's Oncology Group
China Cord Blood Corporation
Chinese Academy of Medical Sciences
Clal Biotechnology Institute
Cognate BioServices
Commissie Voor Klinisch Toegepast Onderzoek
CorCell
Cord Blood America
Corestem
Covance
Cryo-Cell International
CryoCord
Cryo-Save
CuraGen Corporation
CyDex Pharmaceuticals
CyThera
Cytheris
Cytomatrix
Cytori Therapeutics
CXR Biosciences
Dana-Farber Cancer Institute
Denali Ventures
Dendreon Corporation
Depuy
Eastern Cooperative Oncology Group
Eisai
Elbit Imaging
Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA
Eli Lilly and Company
Emory University
Enzon Pharmaceuticals
EpiStem
ES Cell International
European Group for Blood and Marrow Transplantation
European Medicines Agency (EMEA/EMA)
European Organization for Research and Treatment of Cancer - EORTC
Fate Therapeutics
Food and Drug Administration (US FDA)
FCB-Pharmicell
Fibrocell Science
First Affiliated Hospital of Zhejiang University
FortiCell Bioscience
Fred Hutchinson Cancer Research Center
Fresenius Biotech
Gamida Cell
Garnet BioTherapeutics
General BioTechnology
General Hospital of Chinese Armed Police Forces
General Hospital of Guangzhou Military Command of PLA
Genzyme
German Low Grade Lymphoma Study Group
Geron Bio-Med
Geron Corporation
Gilead Sciences
GlaxoSmithKline
Global Stem
GMP Unlimited
Hadassah Medical University
Hannover Clinical Trial Center
Harvard Stem Cell Institute (HSCI)
Harvest Technologies
Health20 (Zero G Cosmeceuticals)
Heinrich Heine University, Dusseldorf
HepaLife Technologies
Histogen
HomeoTherapy
Human Fertilisation and Embryology Authority (HFEA)
ImmunoCellular Therapeutics
Immunovative Therapies
Incyte
IntelliCell Biosciences
International Stem Cell Corporation
International Stemcell Services
InSCeption Biosciences
Instituto de Cardiologia do Rio Grande do Sul
Intercytex
Intermountain Health Care
iPierian
iPS Academia Japan
Isolagen
Israel Healthcare Venture
Israel Stem Cell Society
Ixion Biotechnology
Johann Wolfgang Goethe University Hospital
Johnson & Johnson
Kiadis Pharma
Kilburn & Strode LLP
King's College London
Korea Food and Drug Administration
Korea Stem Cell Bank
Leeds Cancer Centre at St. James's University Hospital
Licensing Solutions
LifebankUSA
Lifebank Cryogenics
Life Cell
LifeStem International
Liu Hua Qiao Hospital
Lonza
MacroPore Biosurgery
Magnafix
MaRS Innovation
Masonic Cancer Center, University of Minnesota
Massachusetts General Hospital
Maxcyte
Mayo Clinic
M.D. Anderson Cancer Center
MD Biosciences
Medac
MedCell Bioscience
Medipost
MedImmune
Medistem
Medizinische Klinik Mannheim
Medtronic
Merck & Co.
Merck Millipore
Meshalkin Research Institute of Pathology of Circulation
Mesoblast
MG Biotherapeutics
Miltenyi Biotec
Ministry of Health, Labour and Welfare (MHLW, Japan)
MK Alliance
Molecular Insight Pharmaceuticals
MolMed
Monash University
Monet Medical
Moorfields Eye Hospital
Mount Sinai Hospital
MultiCell Technologies
Nagoya University
National Cancer Institute
National Heart Institute, Mexico
National Heart, Lung and Blood Institute (NHLB)
National Institute of Allergy and Infectious Diseases (NIAID)
Nippon Zoki Pharmaceutical
National Marrow Donor Program, US
Neostem
Neuralstem
NeuroGeneration
Northern Therapeutics
North West Development Agency
Novartis
NovaThera - part of MedCell Bioscience
Novocell
Noxxon Pharma
NsGene
NuVasive
Odontis
Oligene
Opexa Therapeutics
OrbusNeich
Organogenesis
Orthofix
Osiris Therapeutics
Osteotech
Otsuka Pharmaceutical Development & Commercialization
Ottawa Hospital Research Institute
Parkinson's UK
PDL BioPharma
Pfizer
Pharmastem Therapeutics
Pierre Fabre Medicament
Plasticell
Pluristem Therapeutics
Polyphor
Poniard Pharmaceuticals
Postgraduate Institute of Medical Education and Research
Progencell
Progenitor Cell Therapies
Proneuron Biotechnologies
Quintiles
Rafa Laboratories
Rambam Health Care Campus
Regenavita
Regenerative Medicine Institute of Tijuana
Regenerative Sciences
RegeneRx Biopharmaceuticals
Regenetech
RegenTec
Regimmune
ReInnervate
Reliance Life Sciences
ReNeuron
Renovo
RenovoCyte
Renovo Neural
Reproductive Genetics Institute
RhinoCyte
Ribozyome
RNL Bio Company
Roche
Roslin Cellab
RTI Biologics
Samsung Medical Center
SanBio
Saneron CCEL Therapeutics
Scorpion Medical
Scottish Cancer Therapy Network
S-Evans Biosciences
Shanghai Jiao Tong University School of Medicine
Shenzhen Beike Bio-Technology
Shenzhen Zhongxing Yangfan Biotech
Skye Orthobiologics
Southwest Oncology Group
Spectrum Pharmaceuticals
Spinesmith Partners
State Food and Drug Administration (China)
Stem Cell Authority
StemCells
Stem Cell Innovations
Stem Cell Research Center of Peking University
Stem Cell Sciences
StemCell Services
Stem Cell Therapeutics
StemCell Technologies
StemCore
StemCore Laboratories
StemCyte
Stemedica Cell Technologies
Stemgent
Stemina Biomarker Discovery
Stempath
Stempeutics Research
Stemride International
St Jude Children's Research Hospital
St Mark's Hospital Foundation
St Theresa's Hospital, Bangalore
Swedish Orphan Biovitrum
Swiss Group for Clinical Cancer Research
Systemix
TaiGen Biotechnology
TAP Pharmaceutical Products
Tarix Pharmaceuticals
TCA Cellular Therapy
Technological Park of Ioannina
Technology Strategy Board of the UK Government
Tehran University of Medical Sciences
Tel Aviv University
Tengion
Terumo
Teva Pharmaceutical Industries
Theradigm
Therakos
TheraVitae
Theratechnologies
ThermoFisher Scientific
ThermoGenesis
TiGenix
Tissue Genesis
Tissue Regeneration Technologies
Titan Pharmaceuticals
TotipotentRX Cell Therapy
Toucan Capital
Transition Therapeutics
University College London
Tristem
Tarix Pharmaceuticals
Third Military Medical University
UK Stem Cell Bank
University College London
University Hospital, Caen
University Hospital Carl Gustav Carus
University Hospital, Limoges
University of Heidelberg
University of Kyoto
University of North Carolina
University of Queensland
University of Wisconsin
Vesta Therapeutics
VetCell
ViaCell
ViaCord
ViaCyte
Vical
Vion Pharmaceuticals
ViraCor Laboratories
ViroMed
ViroPharma
Vistagen Therapeutics
Vitro Biopharma
Vitro Diagnostics
Weizmann Institute of Science
WiCell
Xiamen Amoytop Biotech
Xcyte Therapies
XOMA
Yonsei University
Zhejiang Armed Police Hospital
Zhejian First People's Hospital 

 

You have successfully subscribed. Thank you.

An internal error has occurred. Please try again later.

close